89bio
- Company typePublic
- Founded2018
- HeadquartersSan Francisco, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
89bio firmographics
Firmographics- Name
- 89bio
- Legal name
- 89bio, Inc.
- Website
- https://89bio.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
89bio industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where 89bio is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
89bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Biopharmaceutical Product Revenue: As a clinical-stage biopharmaceutical company, 89bio was pre-revenue and did not have any approved products. All revenue would come from future product sales if pegozafermin receives regulatory approval. The company was acquired by Roche in late 2025 before commercializing any products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
89bio product offering
Product offeringCore offering
89bio developed a single clinical-stage therapeutic candidate, pegozafermin (BIO89-100), an investigational glycoPEGylated FGF21 analog being evaluated in Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The asset is designed to act as a master metabolic regulator targeting energy expenditure, glucose metabolism, and lipid metabolism across multiple tissues. The company had no approved or commercialized products prior to its acquisition by Roche in late 2025.
Product overview
89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. The company's sole product candidate is pegozafermin (BIO89-100), an investigational FGF21 analog developed using proprietary glycoPEGylation technology. Pegozafermin is currently in Phase 3 clinical development for two indications: MASH (metabolic dysfunction-associated steatohepatitis) through the ENLIGHTEN trials, and severe hypertriglyceridemia (SHTG) through the ENTRUST trial. The company was acquired by Roche in late 2025.
Differentiator
Problem solved
Functional benefit
Products and services
- Pegozafermin (BIO89-100) Pegozafermin (BIO89-100) is an investigational glycoPEGylated FGF21 analog being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). It is intended for adult patients with progressive liver disease and cardiometabolic conditions where approved or effective treatment options are limited.
Companies that use 89bio
Customer profileSegments2 records
Ideal customer profiles2 records
89bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
89bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- RochecoreRoche entered into a definitive agreement to acquire 89bio for approximately $2.4 billion in cash with total deal value of up to $3.5 billion including contingent payments. The acquisition strengthened Roche's portfolio in cardiovascular, renal, and metabolic diseases, particularly for the treatment of MASH. The transaction was expected to close in Q4 2025, pending regulatory approvals. Roche completed the acquisition of 89bio, integrating the company and its employees into Roche's pharmaceuticals division.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
89bio competitors and assessment
Company assessmentDirect peers
- Inventiva: Inventiva is developing lanifibranor, a pan-PPAR agonist for MASH, competing in the same Phase 3 regulatory race against pegozafermin's ENLIGHTEN program.
- Madrigal Pharmaceuticals: Madrigal developed Rezdiffra (resmetirom), the first FDA-approved MASH therapy. It is the direct competitive benchmark for any new MASH entrant including pegozafermin, sharing the same prescriber base (hepatologists/endocrinologists) and treatment setting.
- Viking Therapeutics: Viking is advancing VK2809 (oral thyroid receptor agonist) and VK2735 (dual GLP-1/GIP) for MASH and obesity-related metabolic disease, positioning as another mid-stage MASH competitor with adjacent cardiometabolic pipeline overlap.
- Akero Therapeutics: Akero is developing efruxifermin, an FGF21 analog (Fc fusion) for MASH, directly competing with 89bio's pegozafermin on the same mechanism and primary indication. Closest mechanistic and clinical competitor.
Broad incumbents
- Novo Nordisk: Novo Nordisk's semaglutide has generated positive MASH Phase 3 data and Ozempic/Wegovy dominate the cardiometabolic landscape that pegozafermin targets, creating indirect but substantial competitive pressure on adoption.
- Eli Lilly: Lilly's tirzepatide (Mounjaro/Zepbound) is being investigated in MASH and the broader tirzepatide franchise addresses obesity and cardiometabolic disease, making Lilly an incumbent competitor with overlapping physician call points and patient population.
- Boehringer Ingelheim (with Zealand Pharma): Boehringer Ingelheim is co-developing survodutide (a GLP-1/glucagon dual agonist) with Zealand Pharma for MASH and obesity, representing a broader-incumbent entrant with significant cardiometabolic commercial infrastructure overlapping 89bio's target market.
- Pfizer: Pfizer has publicly invested in MASH and broader cardiometabolic programs (e.g., via partnerships and internal candidates), representing a large incumbent with the commercial scale to compete in the same prescriber space post any pegozafermin approval.
Emerging players
- Terns Pharmaceuticals: Terns is developing TERN-501 (a thyroid receptor agonist) and other MASH candidates, representing a smaller emerging competitor focused on the same liver indication that pegozafermin targets.
- Galmed Pharmaceuticals: Galmed (now Lipocine) has historically pursued MASH/NASH therapies with aramchol, providing an early-stage peer in the same liver disease space, though with a different mechanism than pegozafermin.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
89bio social profiles
Digital presence89bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
89bio leadership team
Management profileNumber of profiles
Profiles5 records
89bio funding detail
Funding detailFunding overview
Funding rounds9 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
89bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 89bio
What does 89bio do?
89bio developed a single clinical-stage therapeutic candidate, pegozafermin (BIO89-100), an investigational glycoPEGylated FGF21 analog being evaluated in Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The asset is designed to act as a master metabolic regulator targeting energy expenditure, glucose metabolism, and lipid metabolism across multiple tissues. The company had no approved or commercialized products prior to its acquisition by Roche in late 2025.
Is 89bio a public or private company?
89bio is a public company. It is classified as corporate owned and is currently acquired.
When was 89bio founded?
89bio was founded in 2018. It employs 51 to 100 people.
Where is 89bio based?
89bio is headquartered in San Francisco, United States, in the North America region.
How does 89bio make money?
One revenue line is on record: biopharmaceutical Product Revenue.
Who are 89bio's main competitors?
Direct peers on record are Inventiva, Madrigal Pharmaceuticals, Viking Therapeutics and Akero Therapeutics. Broad incumbents are Novo Nordisk, Eli Lilly, Boehringer Ingelheim (with Zealand Pharma) and Pfizer. Emerging players are Terns Pharmaceuticals and Galmed Pharmaceuticals.
Does 89bio have an API?
No public API is recorded for 89bio.
What industry is 89bio in?
89bio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2834.